Detralex 1000mg 30 tablets — Made in France — Free Delivery

Pharmacological properties

Pharmacodynamics. Pharmacology. Detralex has a venotonic and angioprotective effect, reduces the distensibility of veins and venostasis, improves microcirculation, reduces capillary permeability and increases their resistance, and also improves lymphatic drainage, increasing lymphatic outflow.

Preclinical Pharmacology. An experimental animal study using the ischemia / reperfusion model has shown that the use of a micronized purified flavonoid fraction has a more pronounced effectiveness in reducing the permeability of the vascular wall and the release of blood plasma compared with simple diosmin. This result is due to the presence of a protective effect on microcirculation in flavonoids, such as hesperidin, diosmethin, linarin and isoroifolin, which are part of the fraction and are expressed as hesperidin. The decrease in the permeability of the vascular wall and the output of blood plasma, which was observed with the use of the micronized purified flavonoid fraction, is more significant than that observed with the use of simple diosmin and each component of the flavonoid fraction separately.

Clinical pharmacology. The above pharmacological properties have been confirmed in double-blind, placebo-controlled studies using methods that can determine the effect of the preparation on venous hemodynamics.

Dose / effect ratio. The statistically significant dose-dependent effect of the preparation was established in accordance with the following venous plethysmographic parameters: venous volume, venous extensibility, and venous outflow time. The optimal dose / effect ratio was achieved with 2 tablets.

Venotonic activity. Detralex increases venous tone: using venous occlusive plethysmography, a decrease in venous outflow time has been demonstrated.

Microcirculatory activity. In double-blind, placebo-controlled studies, a statistically significant difference was demonstrated between taking the preparation and placebo. In patients with symptoms of capillary fragility, as a result of treatment, their resistance increased, which was determined using angiostereometry.

The preparation also reduces the interaction of leukocytes and endothelium, adhesion of leukocytes in postcapillary venules. This reduces the damaging effect of inflammatory mediators on the walls of the veins and the valve leaflets of the veins.

In clinical practice. In double-blind, placebo-controlled studies, the therapeutic activity of the preparation has been shown in phlebology in the treatment of functional and organic chronic venous insufficiency of the lower extremities, as well as in proctology in the treatment of hemorrhoids.

Pharmacokinetics. The excretion of the active substance occurs mainly with feces. An average of 14% of the dose taken is excreted in the urine. T½ is 11 hours.

The preparation is actively metabolized, as evidenced by the presence of various phenolic acids in the urine.

Indications

Symptomatic treatment of venolymphatic insufficiency (heaviness in the legs, pain, night cramps, edema, trophic disorders, including varicose ulcers). symptomatic treatment of hemorrhoids.

Application

For oral administration. prescribed for adults.

Venolymphatic insufficiency. The recommended dose is 2 tablets per day: 1 tablet during the day and 1 tablet in the evening with meals. After a week of use, you can take 2 tablets per day, once with meals.

Hemorrhoidal disease

Treatment of episodes of acute hemorrhoids: 6 tablets per day for 4 days, then 4 tablets per day for the next 3 days. Take with meals. Divide the daily number of tablets into 2-3 doses. Maintenance therapy - 2 tablets per day.

The duration of therapy is determined by the doctor depending on the indications for use and the course of the disease.

Children. There are no data on the use of Detralex in children.

Contraindications

Hypersensitivity to the active substance or any of the excipients.

Side effects

During clinical studies, with the use of Detralex, side effects of moderate intensity were noted, mainly from the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting).

The following side effects have been reported, which are distributed in frequency of occurrence in this way: very often (≥1 / 10); often (≥1 / 100, 1/10); infrequently (≥1 / 1000, 1/100); rarely (≥1 / 10,000, 1/1000); very rare (1/10 000); the frequency is unknown (cannot be determined from the available information).

Neurological disorders: rarely - dizziness, headache, malaise.

From the gastrointestinal tract: often - diarrhea, dyspepsia, nausea, vomiting; infrequently - colitis; frequency unknown * - pain in the abdominal region.

On the part of the skin and subcutaneous tissue: rarely - rash, itching, urticaria; frequency unknown * - isolated edema of the face, lips, eyelids, in exceptional cases - Quincke's edema.

* Post-marketing observations.

Special instructions

The use of this preparation for acute hemorrhoids does not replace specific treatment and does not interfere with the treatment of other proctological diseases. if the symptoms do not disappear quickly during a short course of treatment, a proctological examination should be carried out and the therapy should be revised.

In case of venous circulation disorders, more effective treatment is provided by a combination of therapy in compliance with the following lifestyle recommendations:

avoid prolonged exposure to the sun, prolonged standing, overweight;

walking and in some cases wearing special stockings to improve blood circulation.

Application during pregnancy or lactation. Pregnancy. Pregnant women should use the preparation with caution. Consult a physician before use. Studies have not shown a teratogenic effect of the preparation, and no side effects have been reported.

Lactation. Due to the lack of data on the penetration of the preparation into breast milk, the use of the preparation during breastfeeding should be avoided.

Fertility Reproductive toxicity studies in animals have shown no effect on fertility.

The ability to influence the reaction rate when driving or working with other mechanisms. Studies on the effect of the flavonoid fraction on the ability to drive vehicles or work with other mechanisms have not been conducted. However, according to the general safety profile of the flavonoid fraction, Detralex has no or little effect on this ability. In case of detection of a side effect of the preparation care must be taken.

Interactions

Interaction studies have not been conducted. however, taking into account the large post-registration experience of using the preparation, to date, no interaction with other preparations has been announced.

Overdose

There are no reports of overdose cases.

Storage conditions

Does not require special storage conditions. Keep out of the reach of children.